Hyperfine, Inc.
HYPR Healthcare Medical Devices
Hyperfine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 44.8%, EPS grew 25.0% and free cash flow grew 13.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow HYPR
Hyperfine, Inc. (HYPR) EV/Sales
As of 16 October 2026, Hyperfine, Inc. (HYPR) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from −121× (March 2022) to 45.4× (April 2022); the current reading is higher than 65% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | 60.95% |
| FY2024 | 2.0× | 366.10% |
| FY2023 | 0.4× | — |
| FY2022 | −8.8× | — |
| FY2021 | −110× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.2× | 23.66% |
| Mar 2026 | 5.0× | 55.14% |
| Dec 2025 | 3.3× | (62.78%) |
| Sep 2025 | 8.7× | 208.00% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OM Outset Medical, Inc. compare | 0.2× |
| LUNG Pulmonx Corporation compare | 0.7× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| LNSR LENSAR, Inc. compare | 1.1× |
| ECOR electroCore, Inc. compare | 1.9× |
| APYX Apyx Medical Corporation compare | 2.2× |
| HYPR Hyperfine, Inc. | 2.6× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| SERA Sera Prognostics, Inc. compare | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)